58 completed. 58 Phase 2, 7 Phase 3, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 58 | Completed 58 |
| Phase 3 | 7 | Completed 7 |
| Phase 1 | 3 | Completed 3 |
Follow Sofosbuvir: new trials by email Literature Review of Sofosbuvir trials Research Report on Sofosbuvir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C Sofosbuvir 400 MG, Ravidasvir 200mg - Hepatitis C | Phase 2 / Phase 3 | Completed | Muhammad Radzi Abu Hassan | 322 | 2021-03-23 | 2025-03-13 |
| COVID-19 Prophylaxis South Africa (COVER HCW) Nitazoxanide, Sofosbuvir/Daclatasvir - Covid19, SARS-CoV Infection | Phase 2 | Completed | University of Witwatersrand, South Africa | 1950 | 2020-12-08 | 2022-06-07 |
| Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19 Paracetamol, Artesunate-amodiaquine, Pyronaridine-artesunate - COVID-19 | Phase 2 | Completed | Shin Poong Pharmaceutical Co. Ltd. | 192 | 2020-09-03 | 2025-07-28 |
| The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC110114 Tablets in HCV-infected Subjects HEC110114 Tablet, Sofosbuvir Tablet - Chronic Hepatitis C | Phase 1 / Phase 2 | Completed | Sunshine Lake Pharma Co., Ltd. | 24 | 2020-07-06 | 2020-09-10 |
| Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1 Narlaprevir, Ritonavir, Sofosbuvir - Chronic Hepatitis c Genotype 1 | Phase 2 | Completed | R-Pharm | 85 | 2019-05-06 | 2022-10-31 |
| Utilization of Hepatitis C Positive Kidneys in Negative Recipients Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET] - Kidney Transplant, Hepatitis C | Phase 2 / Phase 3 | Completed | Ohio State University | 54 | 2019-03-22 | 2023-09-13 |
| Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C] Sofosbuvir, Daclatasvir, Pegylated Interferon alfa-2a - Hepatitis C, Chronic | Phase 2 / Phase 3 | Completed | Johns Hopkins Bloomberg School of Public Health | 150 | 2018-02-02 | 2021-05-18 |
| Ledipasvir/Sofosbuvir for Hepatitis B Virus Infection Ledipasvir 90 MG / Sofosbuvir 400 MG Oral Tablet [Harvoni], Sofosbuvir 400 MG [Sovaldi], Ledipasvir 90 MG - Hepatitis B | Phase 2 | Completed | University of Maryland, Baltimore | 21 | 2018-02-01 | 2021-09-20 |
| A Direct obserVed therApy vs fortNightly CollEction Study for HCV Treatment - ADVANCE HCV Study Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet, Psychological intervention, Sofosbuvir 400 MG - Hepatitis C | Phase 2 | Completed | University of Dundee | 129 | 2018-01-19 | 2021-11-18 |
| HepNet Pilot Trial: Multicenter Trial for the Treatment of Chronic Hepatitis E With Sofosbuvir (SofE) Sofosbuvir - Hepatitis E, Hepatitis Chronic Viral | Phase 2 | Completed | Hannover Medical School | 10 | 2017-12-07 | 2019-03-08 |
| Statins in Chronic Hepatitis C Patients Receiving Sofosbuvir/Daclatasvir Combination Simvastatin 10mg, sofosbuvir plus daclatasvir - Chronic Hepatitis c, Metabolic Syndrome | Phase 2 / Phase 3 | Completed | Ain Shams University | 100 | 2017-12-01 | 2018-09-20 |
| Harvoni Treatment Porphyria Cutanea Tarda Harvoni - Porphyria Cutanea Tarda, Hepatitis C | Phase 2 | Completed | Wake Forest University Health Sciences | 23 | 2017-09-06 | 2023-07-03 |
| Phase 2 Study of Yimitasvir Phosphate Capsules SOF, DAG181 - Chronic HCV Infection | Phase 2 | Completed | Sunshine Lake Pharma Co., Ltd. | 129 | 2017-07-31 | 2020-03-18 |
| Safety and Efficacy of KW-136 and Sofosbuvir for Treatment of Chronic Hepatitis C KW-136, Sofosbuvir - Hepatitis C, Chronic | Phase 2 | Completed | Kawin Technology Share-holding Co., Ltd. | 110 | 2017-02-15 | 2018-01-31 |
| A Phase II Trial of Sofosbuvir (SOF) and GS-5816 for People With Chronic Hepatitis C Virus Infection and Recent Injection Drug Use Sofosbuvir (SOF)/GS-5816 - Hepatitis C | Phase 2 | Completed | Kirby Institute | 103 | 2016-03-16 | 2019-02-27 |
| Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083) Grazoprevir, Elbasvir, Ribavirin - Hepatitis C | Phase 2 | Completed | Merck Sharp & Dohme LLC | 101 | 2016-01-05 | 2019-08-13 |
| Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir Grazoprevir/Elbasvir, Sofosbuvir, Ribavirin - Hepatitis C | Phase 2 | Completed | ANRS, Emerging Infectious Diseases | 26 | 2016-01-01 | 2026-06-12 |
| Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central Africa Sofosbuvir, Ribavirin, Ledipasvir - Hepatitis C, HIV Infection | Phase 2 | Completed | ANRS, Emerging Infectious Diseases | 120 | 2015-10-01 | 2017-12-13 |
| Directly Observed Therapy for HCV in Chennai, India Sofosbuvir, Pegylated Interferon alfa-2a, Ribavirin - Hepatitis C, Chronic | Phase 2 | Completed | Johns Hopkins Bloomberg School of Public Health | 50 | 2015-09-01 | 2021-04-15 |
| Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Tablet Plus Ribavirin Tablet (Part A) Versus Single Dose (2 Tablets) of EHCV Containing Sofosbuvir, Ribavirin, and Natural Anti-hemolytic (B) in Egyptian Adults With Chronic Genotype 4 HCV Infection Two tablets of EHCV in Single Dose each tablet containing SOF 200 mg, RBV 500 mg and Natural anti-hemolytic (AH) at 200 mg, Sofosbuvir tablet (SOF) 400 mg - once daily, Ribavirin (RBV) 1000 mg - splitted on 2 doses daily - 600 mg on morning and 400 mg on evening - Hepatitis c | Phase 2 / Phase 3 | Completed | Egyptian Liver Hospital | 80 | 2015-07-01 | 2016-10-17 |
Showing 20 of 58. Sign in to see all of them.
Hepatitis C (32) · Hepatitis C, Chronic (19) · Hepatitis (7) · Bronchiolitis Obliterans Syndrome (2) · COVID-19 (2) · Directly Observed Therapy (2) · Fibrosis (2) · Carcinoma, Hepatocellular (1) · Digestive System Diseases (1) · Enterovirus Infections (1) · Flaviviridae Infections (1) · HIV Infections (1) · Hemophilia A (1) · Hepatitis A (1) · Hepatitis B (1)
Gilead Sciences (17) · ANRS, Emerging Infectious Diseases (3) · Humanity and Health Research Centre (3) · AbbVie (2) · Bristol-Myers Squibb (2) · Janssen Research & Development, LLC (2) · Johns Hopkins Bloomberg School of Public Health (2) · Merck Sharp & Dohme LLC (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Sunshine Lake Pharma Co., Ltd. (2) · Ain Shams University (1) · Beni-Suef University (1) · Egyptian Liver Hospital (1) · Hannover Medical School (1) · Janssen R&D Ireland (1)
United States (28) · Puerto Rico (10) · New Zealand (8) · China (6) · Australia (4) · France (4) · Egypt (3) · Germany (3) · Spain (3) · Belgium (2) · India (2) · Russia (2) · South Africa (2) · United Kingdom (2) · Cameroon (1)
Robert H. Hyland, DPhil (5) · Robert H Hyland, DPhil (2) · Anuj Gaggar, MD/PhD (1) · Babacar Sylla (1) · Eric Bellissant (1) · Eric Cohen, MD (1) · Eric Rosenthal (1) · Francois Venter, PhD (1) · George KK Lau, MD (1)
PMID 26596948, PMID 23281974, PMID 23499158, PMID 23499440, PMID 23982366, PMID 24209977, PMID 24262278, PMID 24428467, PMID 24983321, PMID 25078309, PMID 25261839, PMID 25304641, PMID 25364884, PMID 25591505, PMID 25622055, PMID 25733369, PMID 26187031, PMID 26261007, PMID 26521268, PMID 26551051, PMID 26551263, PMID 26595450, PMID 26612014, PMID 26691547, PMID 27367295, PMID 27770561, PMID 27790789, PMID 27878906, PMID 27896858, PMID 27917405, PMID 27943563, PMID 28543053, PMID 28719029, PMID 28971875, PMID 29077864, PMID 29193603, PMID 29274193, PMID 29310928, PMID 29439971, PMID 29473975, PMID 30598598, PMID 31222783, PMID 31300820, PMID 31399460, PMID 31520460, PMID 32166305, PMID 32270053, PMID 32531259, PMID 32624195, PMID 33633233
2015 (3), 2014 (2), 2017 (2), R01DA026727 (2), U54DK083909 (1)